Lomustine
- Atc Codes:L01AD02
- CAS Codes:13010-47-4
- PHARMGKB ID:13010-47-4
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Lomustin; Bulgaria: CCNU; Czech Republic: CCNU; Denmark: Lomustine; Finland: Lomustine; France: Belustine; Germany: Cecenu; Greece: Ceenu, Lomustine; Italy: Belustine; Netherlands: Belustine; Poland: Lomustinum; Romania: Ceenu; Slovakia: Ceenu; Sweden: Lomustine; UK: Lomustine.
North America
Canada: Ceenu; USA: Ceenu.
Latin America
Argentina: Ceenu; Brazil: Citostal; Mexico: Ceenu.
Drug combinations
Chemistry
Lomustine: C~9~H~16~ClN~3~O~2~. Mw: 233.70. (1) Urea, N-(2-chloroethyl)-N’-cyclohexyl-N-nitroso-; (2) 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea. CAS-13010-47-4 (1972).
Pharmacologic Category
Antineoplastic Agents; Alkylating Agents. (ATC-Code: L01AD02).
Mechanism of action
Inhibits DNA and RNA synthesis via carbamylation of DNA polymerase, alkylation of DNA, and alteration of RNA, proteins, and enzymes.
Therapeutic use
Treatment of brain tumors and Hodgkin’s disease.
Pregnancy and lactiation implications
Teratogenic effects and embryotoxicity observed in animal studies. Might cause fetal harm when administered to a pregnant woman. Contraindicated during lactation.
Unlabeled use
Non-Hodgkin lymphoma, melanoma, renal carcinoma, lung cancer, colon cancer.
Contraindications
Hypersensitivity to lomustine, any component of the formulation, or other nitrosoureas. Pregnancy.
Warnings and precautions
Hazardous agent. Bone marrow suppression (thrombocytopenia and leukopenia), might lead to bleeding and overwhelming infections in an already compromised patient (use with caution in depressed platelet, leukocyte or erythrocyte counts). Might cause delayed pulmonary toxicity (infiltrates and/or fibrosis). Long-term use may be associated with development of secondary malignancies. Use with caution in hepatic or renal impairment.